Cardiff Oncology Inc expected to post a loss of 16 cents a share - Earnings Preview

Cardiff Oncology

24/07/2026 21:31

Cardiff Oncology Inc CRDF.OQ CRDF.O is expected to  show a fall in quarterly revenue when it reports  results on July 27 (estimated) for the period ending June 30 2026
The San Diego California-based  company is expected to report a 41.6% decrease in revenue to $70.71 thousand from $121 thousand a year ago, according to the mean estimate from 7 analysts, based on LSEG data.
​LSEG's mean analyst estimate for Cardiff Oncology Inc is for a loss of 16 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 4 "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Cardiff Oncology Inc is $7.50, about 794.9% above its last closing price of $0.84
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.14
-0.13
-0.18
Missed
-33.7
Dec. 31 2026
-0.19
-0.19
-0.11
Beat
41.5
Sep. 30 2025
-0.21
-0.20
-0.17
Beat
16.9​
Jun. 30 2025
-0.19
-0.19
-0.21
Missed
-9.1
​​Mar. 31 2025
-0.18
-0.19
-0.20
Missed
-7.4
Dec. 31 2024
-0.23
-0.24
-0.22
Beat
9​
Sep. 30 2024
-0.27
-0.27
-0.25
Beat
7.4
Jun. 30 2024
-0.25
-0.26
Missed
-5.1
This summary was machine generated July 24 at 20:31 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)